Company: TEM
Filing Date: 2025-04-23
Form Type: 8-K
Source: 0001193125-25-090062
Chunk: 1

Company: Tempus AI, Inc.
Filing Date: 2025-04-23
Form: 8-K
Item: Item 8.01
Chunk 1
---
 and the right of sublicense to AstraZeneca), and (v) in consideration of Pathos’ commitments under the Pathos Master Agreement, Tempus will pay Pathos $35 million. Pathos, in its sole discretion, may pay up to 50% of the data license fees owed to Tempus in shares of Pathos’ Series D Preferred Stock.

Tempus is not a party to the SPA between AstraZeneca and Pathos and makes no representations or warranties about its terms.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Tempus AI, Inc.                               
  By:                  /s/ James Rogers         
                       James Rogers             
                       Chief Financial Officer